Literature DB >> 23364221

The prevalence, impact and economic implications of atrial fibrillation in stroke: what progress has been made?

Nadine E Andrew1, Amanda G Thrift, Dominique A Cadilhac.   

Abstract

Atrial fibrillation (AF) is a major risk factor for stroke, especially in the elderly. Increased life expectancies mean that AF-related stroke is a growing global public health concern. Improvements in the detection, treatment and prevention of the consequences of AF have occurred in recent years. However, the extent to which these improvements have impacted on the prevalence of AF, the risk of AF-related stroke and subsequent economic costs are unknown. This review provides a contemporary assessment of the epidemiological data on AF-related stroke aimed at assessing the effectiveness of primary prevention strategies and associated economic implications with reductions in stroke incidence. A systematic review of the literature was performed. Appropriately designed studies were identified and retrieved. Evidence on changes in the prevalence of AF, the risk of stroke associated with AF and the excess cost of AF-related stroke over the last 30 years was summarised. The results provide evidence that the age-adjusted prevalence of AF and the relative risk of stroke associated with AF has remained relatively constant. Unless action is taken to improve detection of AF and reduce its consequences, a considerable increase in the social and economic burden associated with AF-related stroke is likely.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 23364221     DOI: 10.1159/000343667

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  12 in total

1.  The economic burden of ischemic stroke and major hemorrhage in medicare beneficiaries with nonvalvular atrial fibrillation: a retrospective claims analysis.

Authors:  Kathryn Fitch; Jonah Broulette; Winghan Jacqueline Kwong
Journal:  Am Health Drug Benefits       Date:  2014-06

Review 2.  Paroxysmal Atrial Fibrillation: Novel Strategies for Monitoring and Implications for Treatment in Stroke.

Authors:  Scott B Silverman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-08

3.  XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia.

Authors:  Ping-Yen Liu; Eue-Keun Choi; Tae-Seok Kim; Jen-Yuan Kuo; Jung Myung Lee; Young Keun On; Sang-Weon Park; Hyung-Wook Park; Dong-Gu Shin; Lili Wang; Hsueh-Wei Yen; Moon-Hyoung Lee
Journal:  Adv Ther       Date:  2022-05-26       Impact factor: 4.070

4.  Efficacy of Electrical Cardioversion in Relation to Occurrence and Type of Functional Mitral Regurgitation in Patients with Atrial Fibrillation.

Authors:  Konrad Klocek; Katarzyna Klimek; Michał Tworek; Karolina Wrona-Kolasa; Małgorzata Cichoń; Maciej Wybraniec; Katarzyna Mizia-Stec
Journal:  J Clin Med       Date:  2022-04-07       Impact factor: 4.964

5.  Cardiac diagnostic work-up for atrial fibrillation after transient ischaemic attacks in England and Wales: results from a cross-sectional survey.

Authors:  Olivia Geraghty; Eleni Korompoki; Filippos T Filippidis; Anthony Rudd; Roland Veltkamp
Journal:  BMJ Open       Date:  2016-11-10       Impact factor: 2.692

Review 6.  The complexity of atrial fibrillation newly diagnosed after ischemic stroke and transient ischemic attack: advances and uncertainties.

Authors:  Joshua O Cerasuolo; Lauren E Cipriano; Luciano A Sposato
Journal:  Curr Opin Neurol       Date:  2017-02       Impact factor: 5.710

7.  Low prevalence of atrial fibrillation in ischaemic stroke: Underestimating a modifiable risk factor.

Authors:  Mohammed Mayet; Kamil Vallabh; Clint Hendrikse
Journal:  Afr J Emerg Med       Date:  2020-11-19

8.  Morning hypertension is a risk factor of macrovascular events following cerebral infarction: A retrospective study.

Authors:  Qinhua Wu; Jianfeng Qu; Yong Yin; Aihong Wang; Wei Cheng; Ruikang Duan; Bin Zhang
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

9.  Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin.

Authors:  Mark Alberts; Yen-Wen Chen; Jennifer H Lin; Emily Kogan; Kathryn Twyman; Dejan Milentijevic
Journal:  Stroke       Date:  2019-12-31       Impact factor: 7.914

10.  Benefits of prescribing low-dose digoxin in atrial fibrillation.

Authors:  Ciprian Ilie Rosca; Nilima Rajpal Kundnani; Anca Tudor; Maria-Silvia Rosca; Violeta-Ariana Nicoras; Gabriela Otiman; Elena Ciurariu; Alin Ionescu; Morariu Stelian; Abhinav Sharma; Claudia Borza; Daniel Florin Lighezan
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.